News
AstraZeneca Joins Pharma Investment Push in U.S
Digest more
That’s how long it took from the time AstraZeneca CEO Pascal Soriot greeted Virginia Governor Glenn Youngkin in his London ...
Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen.
AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic ...
MUNICH/WASHINGTON] AstraZeneca plans to invest US$50 billion in the US before 2030, becoming the latest European pharma company to ratchet up spending in the country ahead of potential tariffs on ...
1d
AstraZeneca (LSE:AZN) recently announced positive developments regarding TAGRISSO®'s survival benefits in treating non-small ...
AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...
AstraZeneca inks a multibillion-dollar deal with CSPC to co-develop AI-driven therapies for chronic and immune diseases, boosting its presence in China.
Sino Biopharmaceuticals plans to pay up to $950.9 million to acquire LaNova Medicines, which previously licensed drugs to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback